EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Mitochondrial “swap” in the Tumor Microenvironment
Professor, Okayama University
Yosuke Togashi MD PhD is a Professor at Okayama University specializing in tumor microenvironment research He trained in respiratory medicine earned his PhD in genome biology and began cancer immunology research in
Articles
Metabolic Stability
The liability of a drug substance to the metabolism is referred to as metabolic stability The liver uses CYPmediated metabolism to clear most orally administered drugs Metabolic stability data is essential for evaluating and optimising the human therapeutic dose for the drug In vitro systems obtained fromthe human liver such as microsomes and hepatocytes
Research Insights
Baseline Characteristics of SARS-CoV-2 Vaccine Non-responders in a Large Population-based Sample
Individuals with certain malignancies organ transplant recipients and immunecompromised individuals could mount either an incomplete or suboptimal antibody response to primary series vaccination
Case Studies
Labile Biologics - Stable Aqueous Formulation of Recombinant Factor VIII
Challenge All marketed Factor VIII products are lyophilised preparations produced by either recombinant technology or purified from pooled plasma The preparations are typically stabilised by addition of sugars Administration of the lyophilised product is a very complex procedure involving a number
Techno Trends
Ensysce Biosciences Launched Ground Breaking PF614-MPAR Product for Oral Overdose Protection
Ensysce Biosciences has launched its groundbreaking product PFMPAR as the inaugural opioid of its kind designed to offer oral overdose protection across all drug classes
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The New Pharmacovigilance Era
With over 15 years of experience, Aarti brings deep expertise across pharmaceutical contract research services and technology‑enabled drug discovery and development. She leads the Contract Research Services program, covering peripheral and ancillary service segments such as tech vendors, eClinical solution providers, central labs, and related ecosystems. Her strengths span market intelligence, forecasting, competitive benchmarking, and strategic opportunity assessment as well as growth advisory services, that consistently support executive decision‑making for global clients. She is regarded as a trusted growth expert, and is adept in supporting stakeholders navigate industry disruption, accelerate innovation, and seize transformative opportunities across the rapidly evolving Contract Services Landscape.
Natural Polymers and Fibers in Drug Delivery
Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.
Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.
Computational Approach towards Designing Potent Inhibitors for Tuberculosis
Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.
Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.
Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.
The Role of Artificial Intelligence in Advancing Pharmacovigilance Systems
Rahul Jaiswal is an Assistant Professor at Hygia College of Pharmacy, Lucknow, and a Research Scholar at Integral University, Lucknow. He has been associated with CSIR-CDRI, Lucknow, and has published several articles. His expertise includes molecular techniques, histopathology, and innovative pharmaceutical research, with contributions to national and international conferences.
APAC’s Rising Role in Neurodegenerative Disease Research and Development
Simona Lambertini is a senior global clinical research leader with nearly 20 years of experience in international clinical development, research strategy and stakeholder engagement. She has led complex multicountry programs across Europe, North America and the Middle East, collaborating with pharma, biotech and research institutions across high-complexity therapeutic areas.
press releasesRead more...
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength
Celltrion KRX today announced the launch of the mg strength of Omlyclo omalizumab a treatment for chronic spontaneous urticaria and allergic asthma in Europe With the addition
ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation
The Hong Kong Applied Science and Technology Research Institute ASTRI and Saint Francis University SFU have signed a Memorandum of Understanding MoU to establish a strategic partnership focused on advancing
UQ-Thermo Fisher Scientific partnership to advance minerals, biomedical research
The University of Queensland andThermoFisher Scientific have committed to accelerating clean energy advancedmanufacturingand biomedical science as part of a new FrameworkAgreement
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
Haisco Pharmaceutical Group Co Ltd Haisco Ticker Code announced that it has entered into an exclusive licensing agreement with Sentivera a new US venture founded by Population Health Partners
Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
GSK plc LSENYSE GSK today announced that Japans Ministry of Health Labour and Welfare MHLW has approved Hibsago bepirovirsen an antisense oligonucleotide ASO as a functional cure for chronic
EventsRead more...
25 - 27
Aug 2026CPHI Korea 2026
COEX, Seoul, Korea
26 - 27
Aug 2026BIOMEDevice 2026
Boston Convention & Exhibition...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
LATEST NEWSRead more...
Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer
Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable
BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients
BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years
Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1
Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults
Johnson & Johnson’s IMAAVY Approved in the US as First Treatment for Warm Autoimmune Haemolytic Anaemia
Johnson Johnson has announced that the US Food and Drug Administration FDA has approved IMAAVY nipocalimabaahu for the treatment of warm autoimmune haemolytic anaemia wAIHA in adults and children aged years and older who are currently or previously treated with corticosteroids
Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan
Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange has received marketing approval in Japan for its generic pomalidomide capsules in mg mg mg and mg strengths following a review
Ultragenyx Receives U.S. FDA Approval for GENGLYCOS Gene Therapy for Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc NASDAQ RARE has received accelerated approval from the US Food and Drug Administration FDA for GENGLYCOS pariglasgene brecaparvovecopnr also known as DTX for adults and children aged eight years and older with glycogen storage disease type Ia GSDIa